Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Physician
Patient
Health Care Practitioner
Pharma / Biotech Industry
Other
Topics:
General Internal Medicine
•
Gastroenterology
•
General Hepatology
•
Alcohol-associated Liver Disease
What pharmacologic therapies do you use to treat alcohol use disorder in a patient with cirrhosis?
Related Questions
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
How do you approach the treatment of Crohn's colitis in the setting of immunosuppression for liver transplant?
How would you workup an elevated IgG level in which there is no evidence of cirrhosis or autoimmune hepatitis on liver biopsy?
Do you obtain liver biopsy to confirm the diagnosis of cirrhosis if cirrhotic liver morphology is noted on imaging?
Would you consider sotalol to be a suitable non-selective beta blocker for primary prevention of variceal bleeding in a patient who requires sotalol for treatment of arrhythmia in the setting of Fontan-associated liver disease and clinically significant portal hypertension?
How do you manage persistent rectal bleeding in the setting of rectal adenocarcinoma in a treatment-naive patient?
When would you phlebotomize patients with secondary hemochromatosis, such as due to NAFLD/cirrhosis?
Is there a serum ammonium level for which you recommend initiation of dialysis in a patient with hepatic encephalopathy?
How would you approach the workup of a patient with a history of HCC post-TARE with a recent non-viable MRI but a new portal vein thrombosis?
When do you send for genetic testing (e.g., SPINK1, PRSS1, CFTR) in a patient with recurrent or chronic pancreatitis without an obvious etiology and how does it impact your management?
